Report cover image

Virology Market By Type (Diagnostics Test, Antiviral Therapeutics, Viral Infection Controlling Techniques, Interferons) , By Application (Skin & Soft Tissues Infections, GI Tract Infections, Sexually Transmitted Diseases, Others) : Global Opportunity Anal

Publisher Allied Market Research
Published Sep 01, 2024
Length 320 Pages
SKU # ALMR19510404

Description

Virology Market By Type (Diagnostics Test, Antiviral Therapeutics, Viral Infection Controlling Techniques, Interferons) , By Application (Skin & Soft Tissues Infections, GI Tract Infections, Sexually Transmitted Diseases, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033


Virology Market Expected to Garner $4.6 Billion by 2033, Growing at a CAGR of 5.5%

The global virology market is expected to grow primarily due to the growing infections due to new pathogen detection & spread. The Asia-Pacific region is predicted to witness profitable growth by 2033.

As per the report published by Research Dive, the global virology market was valued at $2.7 billion in 2023 and is expected to register a revenue of $4.6 billion by 2033 at a CAGR of 5.5% during the forecast period 2024-2033.

Dynamics of the Market

The increasing incidence of emerging infections due to new pathogen detection & spread, rising need for innovative antiviral drugs, vaccines, and diagnostic tools to combat emerging disease, and growing R&D efforts for effective treatments are expected to make the virology market a highly profitable one during the forecast period.

However, according to market analysts, high costs and stringent regulatory approval processes might restrain the growth of the market.

Rapid evolution in diagnostic technologies, like multiplex RT-PCR and microarray analysis, and continued refinement & standardization of new diagnostic technologies present significant opportunities for virology market growth. Moreover, partnerships & collaborations accelerate innovation in virology research and product development.

Key Players of the Market

The major players of the virology market include GlaxoSmithKline plc, Boehringer Ingelheim Corporation, Abbott Laboratories, Merck and Co. Inc., Siemens, Novartis International AG, Johnson & Johnson, Roche, AstraZeneca AB, and Trinity Biotech.

What the Report Covers

In addition to the details highlighted in this description, the comprehensive final report delves into essential market aspects. These encompass a market overview, SWOT analysis, market dynamics, Porter’s five forces analysis, segmentation (key trends, regional analysis, and forecast analysis), and company profiles (including company overview, product portfolio, operating segments, strategic initiatives, and financial performance).

Key Market Segments

By Type

Diagnostics Test
Antiviral Therapeutics
Viral Infection Controlling Techniques
Interferons

By Application

Skin Soft Tissues Infections
GI Tract Infections
Sexually Transmitted Diseases
Others

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
UAE
Rest of LAMEA

Key Market Players

GlaxoSmithKline Plc.
Abbott Laboratories
Boehringer Ingelheim Corporation
Merck and Co. Inc.
Novartis International Ag
Siemens
Johnson & Johnson
AstraZeneca AB
Roche
Trinity Biotech

Table of Contents

320 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VIROLOGY MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Diagnostics Test
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Antiviral Therapeutics
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Viral Infection Controlling Techniques
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Interferons
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: VIROLOGY MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Skin Soft Tissues Infections
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. GI Tract Infections
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Sexually Transmitted Diseases
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Others
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
CHAPTER 6: VIROLOGY MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By Application
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Virology Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By Application
6.2.6. Canada Virology Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By Application
6.2.7. Mexico Virology Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By Application
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By Application
6.3.4. Market Size and Forecast, By Country
6.3.5. France Virology Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By Application
6.3.6. Germany Virology Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By Application
6.3.7. Italy Virology Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By Application
6.3.8. Spain Virology Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By Application
6.3.9. UK Virology Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By Application
6.3.10. Rest Of Europe Virology Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By Application
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By Application
6.4.4. Market Size and Forecast, By Country
6.4.5. China Virology Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By Application
6.4.6. Japan Virology Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By Application
6.4.7. India Virology Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By Application
6.4.8. South Korea Virology Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By Application
6.4.9. Australia Virology Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By Application
6.4.10. Rest of Asia-Pacific Virology Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By Application
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By Application
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Virology Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By Application
6.5.6. South Africa Virology Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By Application
6.5.7. Saudi Arabia Virology Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By Application
6.5.8. UAE Virology Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By Application
6.5.9. Rest of LAMEA Virology Market
6.5.9.1. Market Size and Forecast, By Type
6.5.9.2. Market Size and Forecast, By Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. GlaxoSmithKline Plc.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Abbott Laboratories
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Boehringer Ingelheim Corporation
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Merck And Co. Inc.
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Novartis International Ag
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Siemens
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Johnson And Johnson
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. AstraZeneca AB
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Roche
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Trinity Biotech
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 2. VIROLOGY MARKET FOR DIAGNOSTICS TEST, BY REGION, 2024 - 2033 ($MILLION)
TABLE 3. VIROLOGY MARKET FOR ANTIVIRAL THERAPEUTICS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 4. VIROLOGY MARKET FOR VIRAL INFECTION CONTROLLING TECHNIQUES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 5. VIROLOGY MARKET FOR INTERFERONS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 6. GLOBAL VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 7. VIROLOGY MARKET FOR SKIN SOFT TISSUES INFECTIONS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 8. VIROLOGY MARKET FOR GI TRACT INFECTIONS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 9. VIROLOGY MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 10. VIROLOGY MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 11. VIROLOGY MARKET, BY REGION, 2024 - 2033 ($MILLION)
TABLE 12. NORTH AMERICA VIROLOGY MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 13. NORTH AMERICA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 14. NORTH AMERICA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 15. U.S. VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 16. U.S. VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 17. CANADA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 18. CANADA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 19. MEXICO VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 20. MEXICO VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 21. EUROPE VIROLOGY MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 22. EUROPE VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 23. EUROPE VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 24. FRANCE VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 25. FRANCE VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 26. GERMANY VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 27. GERMANY VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 28. ITALY VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 29. ITALY VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 30. SPAIN VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 31. SPAIN VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 32. UK VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 33. UK VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 34. REST OF EUROPE VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 35. REST OF EUROPE VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 36. ASIA-PACIFIC VIROLOGY MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 37. ASIA-PACIFIC VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 38. ASIA-PACIFIC VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 39. CHINA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 40. CHINA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 41. JAPAN VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 42. JAPAN VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 43. INDIA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 44. INDIA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 45. SOUTH KOREA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 46. SOUTH KOREA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 47. AUSTRALIA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 48. AUSTRALIA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 51. LAMEA VIROLOGY MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 52. LAMEA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 53. LAMEA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 54. BRAZIL VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 55. BRAZIL VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 56. SOUTH AFRICA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 57. SOUTH AFRICA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 58. SAUDI ARABIA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 59. SAUDI ARABIA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 60. UAE VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 61. UAE VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 62. REST OF LAMEA VIROLOGY MARKET, BY TYPE, 2024 - 2033 ($MILLION)
TABLE 63. REST OF LAMEA VIROLOGY MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 64. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
TABLE 65. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 66. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 67. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 68. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 70. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 71. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 72. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 73. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. BOEHRINGER INGELHEIM CORPORATION: KEY EXECUTIVES
TABLE 75. BOEHRINGER INGELHEIM CORPORATION: COMPANY SNAPSHOT
TABLE 76. BOEHRINGER INGELHEIM CORPORATION: OPERATING SEGMENTS
TABLE 77. BOEHRINGER INGELHEIM CORPORATION: PRODUCT PORTFOLIO
TABLE 78. BOEHRINGER INGELHEIM CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 79. MERCK AND CO. INC.: KEY EXECUTIVES
TABLE 80. MERCK AND CO. INC.: COMPANY SNAPSHOT
TABLE 81. MERCK AND CO. INC.: OPERATING SEGMENTS
TABLE 82. MERCK AND CO. INC.: PRODUCT PORTFOLIO
TABLE 83. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. NOVARTIS INTERNATIONAL AG: KEY EXECUTIVES
TABLE 85. NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
TABLE 86. NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
TABLE 87. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 88. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89. SIEMENS: KEY EXECUTIVES
TABLE 90. SIEMENS: COMPANY SNAPSHOT
TABLE 91. SIEMENS: OPERATING SEGMENTS
TABLE 92. SIEMENS: PRODUCT PORTFOLIO
TABLE 93. SIEMENS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 95. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 96. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 97. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 98. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. ASTRAZENECA AB: KEY EXECUTIVES
TABLE 100. ASTRAZENECA AB: COMPANY SNAPSHOT
TABLE 101. ASTRAZENECA AB: OPERATING SEGMENTS
TABLE 102. ASTRAZENECA AB: PRODUCT PORTFOLIO
TABLE 103. ASTRAZENECA AB: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. ROCHE: KEY EXECUTIVES
TABLE 105. ROCHE: COMPANY SNAPSHOT
TABLE 106. ROCHE: OPERATING SEGMENTS
TABLE 107. ROCHE: PRODUCT PORTFOLIO
TABLE 108. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. TRINITY BIOTECH: KEY EXECUTIVES
TABLE 110. TRINITY BIOTECH: COMPANY SNAPSHOT
TABLE 111. TRINITY BIOTECH: OPERATING SEGMENTS
TABLE 112. TRINITY BIOTECH: PRODUCT PORTFOLIO
TABLE 113. TRINITY BIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL VIROLOGY MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF VIROLOGY MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN VIROLOGY MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVIROLOGY MARKET
FIGURE 10. GLOBAL VIROLOGY MARKET SEGMENTATION, BY TYPE
FIGURE 11. VIROLOGY MARKET FOR DIAGNOSTICS TEST, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 12. VIROLOGY MARKET FOR ANTIVIRAL THERAPEUTICS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 13. VIROLOGY MARKET FOR VIRAL INFECTION CONTROLLING TECHNIQUES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 14. VIROLOGY MARKET FOR INTERFERONS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 15. GLOBAL VIROLOGY MARKET SEGMENTATION, BY APPLICATION
FIGURE 16. VIROLOGY MARKET FOR SKIN SOFT TISSUES INFECTIONS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 17. VIROLOGY MARKET FOR GI TRACT INFECTIONS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 18. VIROLOGY MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 19. VIROLOGY MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 24. COMPETITIVE DASHBOARD
FIGURE 25. COMPETITIVE HEATMAP: VIROLOGY MARKET
FIGURE 26. TOP PLAYER POSITIONING, 2023
FIGURE 27. GLAXOSMITHKLINE PLC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 28. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 29. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 30. ABBOTT LABORATORIES: NET SALES, 2021-2023 ($MILLION)
FIGURE 31. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. BOEHRINGER INGELHEIM CORPORATION: NET SALES, 2021-2023 ($MILLION)
FIGURE 34. BOEHRINGER INGELHEIM CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. BOEHRINGER INGELHEIM CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. MERCK AND CO. INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 37. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. NOVARTIS INTERNATIONAL AG: NET SALES, 2021-2023 ($MILLION)
FIGURE 40. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. SIEMENS: NET SALES, 2021-2023 ($MILLION)
FIGURE 43. SIEMENS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. SIEMENS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($MILLION)
FIGURE 46. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. ASTRAZENECA AB: NET SALES, 2021-2023 ($MILLION)
FIGURE 49. ASTRAZENECA AB: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. ASTRAZENECA AB: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. ROCHE: NET SALES, 2021-2023 ($MILLION)
FIGURE 52. ROCHE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. ROCHE: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. TRINITY BIOTECH: NET SALES, 2021-2023 ($MILLION)
FIGURE 55. TRINITY BIOTECH: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. TRINITY BIOTECH: REVENUE SHARE, BY REGION, 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us